Skip to main content

A single dose of a CD137 antibody-drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD.

Publication ,  Journal Article
Gerdemann, U; Kimler, K; Warren, MR; McGuckin, C; Fleming, RA; D'Ambra, MR; Eran, A; Albanese, A; Chen, E; Winschel, M; Cagnin, L; Lane, J ...
Published in: Blood
August 28, 2025

Rapid CD137 upregulation on alloreactive T cells upon allogeneic stimulation suggests that their selective elimination could prevent acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (HCT). Here, we developed a novel aGVHD prophylactic regimen consisting of a single dose of an anti-CD137 antibody-drug conjugate (CD137-ADC) administered on the day of transplant without additional immunosuppression. The CD137-ADC depleted both human and nonhuman primate (NHP) activated T cells and proved highly effective in preventing xenogeneic aGVHD in mice receiving human peripheral blood mononuclear cells, as well as in NHP undergoing major histocompatibility complex (MHC)-haploidentical HCT. Flow cytometry analysis of NHP T cells indicated specific depletion of activated PD-1+ CD4 and CD8 T cells, while sparing naïve and PD-1-OX40+ memory T-cell subsets during the first week after HCT. CD137-ADC-treated NHP recipients demonstrated robust hematopoietic and immune reconstitution. Hallmarks of T-cell recovery after CD137-ADC, which were associated with long-term aGVHD-free survival, included reconstitution of CD4 memory T cells expressing TRAIL, terminally differentiated CD8 T cells expressing CX3CR1, and CD4 FoxP3+ regulatory T cells, cell types not expected to be involved in aGVHD pathogenesis. CD137-ADC-treated recipients demonstrated a higher risk of reactivation of rhesus lymphocryptovirus (the rhesus macaque Epstein-Barr virus analog), which was associated with reconstitution of follicular helper T cells, interferon signaling-associated memory, and γδT-cell subsets. This reactivation was controllable with rituximab administration. These results document effective depletion of alloreactive T cells and prevention of aGVHD after a single dose of CD137-ADC, suggesting that clinical translation should be carefully explored.

Duke Scholars

Published In

Blood

DOI

EISSN

1528-0020

Publication Date

August 28, 2025

Volume

146

Issue

9

Start / End Page

1127 / 1141

Location

United States

Related Subject Headings

  • Tumor Necrosis Factor Receptor Superfamily, Member 9
  • Transplantation, Homologous
  • Mice
  • Male
  • Macaca mulatta
  • Immunology
  • Immunoconjugates
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Graft vs Host Disease
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gerdemann, U., Kimler, K., Warren, M. R., McGuckin, C., Fleming, R. A., D’Ambra, M. R., … Tkachev, V. (2025). A single dose of a CD137 antibody-drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD. Blood, 146(9), 1127–1141. https://doi.org/10.1182/blood.2024027239
Gerdemann, Ulrike, Kyle Kimler, Matthew R. Warren, Connor McGuckin, Ryan A. Fleming, Matthew R. D’Ambra, Alal Eran, et al. “A single dose of a CD137 antibody-drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD.Blood 146, no. 9 (August 28, 2025): 1127–41. https://doi.org/10.1182/blood.2024027239.
Gerdemann U, Kimler K, Warren MR, McGuckin C, Fleming RA, D’Ambra MR, et al. A single dose of a CD137 antibody-drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD. Blood. 2025 Aug 28;146(9):1127–41.
Gerdemann, Ulrike, et al. “A single dose of a CD137 antibody-drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD.Blood, vol. 146, no. 9, Aug. 2025, pp. 1127–41. Pubmed, doi:10.1182/blood.2024027239.
Gerdemann U, Kimler K, Warren MR, McGuckin C, Fleming RA, D’Ambra MR, Eran A, Albanese A, Chen E, Winschel M, Cagnin L, Lane J, Gorfinkel L, Adams B, Kwun J, Lanieri L, Hoban M, Lamothe TL, Hyzy S, Olson LM, Panoskaltsis-Mortari A, Prockop SE, Blazar BR, Kean LS, Tkachev V. A single dose of a CD137 antibody-drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD. Blood. 2025 Aug 28;146(9):1127–1141.

Published In

Blood

DOI

EISSN

1528-0020

Publication Date

August 28, 2025

Volume

146

Issue

9

Start / End Page

1127 / 1141

Location

United States

Related Subject Headings

  • Tumor Necrosis Factor Receptor Superfamily, Member 9
  • Transplantation, Homologous
  • Mice
  • Male
  • Macaca mulatta
  • Immunology
  • Immunoconjugates
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Graft vs Host Disease